

**PDA Europe Conference, Exhibition, Education** 

# **Parenteral Packaging**

Join us in our annual professional exchange on the latest on primary containers and test methods of container closure systems.



14-15 March 2017

Hotel Porta Fira Barcelona | Spain

#### LETTER FROM THE CO-CHAIRS

Dear Colleagues,

You are warmly invited to join us in our ongoing professional discourse of latest manufacturing technologies and business trends in the Parenteral Packaging arena.

#### SCIENTIFIC PROGRAM PLANNING COMMITTEE

Roger Asselta, Genesis Packaging, Co-Chair

Derek Duncan, LIGHTHOUSE, Co-Chair

**Bettine Boltres, SCHOTT** 

Renaud Janssen, Datwyler

Enric Jo, ReigJofré

Roman Mathaes, LONZA

Galen Shi, Eli Lilly

Michael Spallek, Rommelag ENGINEERING

**Daniel Wagner,** Sanofi

Klaus Wuchner, Janssen J&J

Jörg Zürcher, Bayer

Sylvia Becker, PDA Europe

Georg Roessling, PDA Europe

PDA Europe's Conference has proven to be a must-attend event for professionals in this field.

Join us in Barcelona / Spain, 14-15 March 2017 to continue and further deepen scientific advancements and understanding of topics previously raised in this successful annual event.

As proper packaging of pharmaceuticals is crucial to drug stability, this conference and the accompanying exhibition address quality of components and containers as much as aspects of processing, product distribution and storage. Excellent speakers from the industry, regulatory and academia will give detailed information about opportunities and challenges the advancing pharmaceutical packaging market faces.

The conference aims to keep its attendees updated about all regulatory aspects involved in the parenteral packaging process, such

as new regulations from European and US agencies, the revision of Annex 1, and PDA Technical Reports.

Different materials such as glass, polymers & elastomers and their characteristics regarding supplier issues and end-user preferences will also be discussed, as well as the design of primary and secondary packaging.

The role of Container Closure Integrity (CCI) in product-package development, post-approval product changes and routine manufacturing will be explored, and information on aseptic processing will be given.

Of equal importance to the content is to interact with the speakers and your fellow attendees. Barcelona will offer a comfortable yet exciting atmosphere for exchange during refreshment breaks, on-site lunches and evening receptions.

Join PDA Europe's Parenteral Packaging Conference in one of the most beautiful cities in the world.

Welcome to Barcelona!

Roger Asselta, Genesis Packaging, Co-Chair

Derek Duncan, LIGHTHOUSE, Co-Chair

		SCHEDULE AT A GLANCE	
13 March	10:00 - 17:30	Pre-filled Syringes	Interest Group Meeting
13 March	9:00 - 18:00	Elastomers	Training Course
13 March	13:00 - 18:00	Secondary Packaging for Parenterals	Pre-Conference Workshop
	9:00 - 18:30	Parenteral Packaging	Conference, Exhibition
15 March	7:30 - 9:00	Open Forum: Packaging Science Interest Group (IG) Meeting	Interest Group Meeting
	9:00 - 17:00	Parenteral Packaging	Conference, Exhibition
16 March	9:00 - 17:00	Container Closure Development	Training Course
16 March 17 March	9:00 - 18:00 9:00 - 16:30	Container Closure Integrity Testing	Training Course
16 March 17 March	9:00 - 18:30 8:30 - 16:00	Track and Trace	Training Course
16 March 17 March	9:00 - 18:00 9:00 - 16:30	Extractables & Leachables	Training Course

For latest information, please visit: **pda.org/eu-parpack-2017** 





# **PDA Europe Interest Group Meeting**

# **Pre-filled Syringes**



## **Product Lifecycle Management (PLM)**

Want to create value for your injectable drug? Consider a Pre-filled Syringe / Device! PLM is critical for pharmaceutical and biotechnology manufacturers, especially when considering the enormity of the expense, time and effort it takes to bring a drug to fruition. Get involved and talk at the meeting. Make use of the open forum a small Interest Group has to offer. Gain first-hand information about activities of the 'Interest Group Pre-filled Syringes'.

- Case Studies
- PLM Strategies
- Formulation Challenges
- Primary Packaging and Secondary Packaging
- Risk Management and Quality by Design
- Technology Transfers
- Regulatory Trends
- Collaboration with suppliers

A Roundtable Discussion: Business Drivers for Product Life Cycle Management

Make sure to register you and your colleagues for this Interest Group Meeting online.

Register by 13 Feb 2017 and SAVE!

13 March 2017

lay, 13 March 2017	
Welcome and Introduction	Georg Roessling, PDA Europe
IG Activities	Brigitte Reutter-Haerle, <i>Vetter</i>
Focus Topic: Moderato Life Cycle Management: From Pre-filled to Syringes / Combination Products	r: Brigitte Reutter-Haerle, Vetter
Life Cycle Management: Best Practices and Pitfalls	Christian Herget, BD Medical
Coffee Break	
Fully Integrated Safety System: A New Option for the Product Life Cycle Management from Vial to PFS	Alessandro Morandotti, <i>OMPI</i>
PLAJEX™ and Safe'n'Sound® - Compatibility Established to Serve Pharma Clients for Product Life Cycle Management	Adrien Tisserand, <i>Nemera</i> William Dierick, <i>Terumo</i>
Case Study: A Supplier's Perspective	Holger Krenz, SiO2 Medical Products
Lunch Break	
PDA Interactive: Moderators Roundtable Discussions of Different Case Studies	s: <b>Christian Herget,</b> BD Medical
	Ian Thompson & Andreas Schneider, Ypsomed
Case Study A: LCM - From Lyo Vial to Pre-filled Syringe	
Constitution of the Consti	
Case Study B: LCM- From Pre-filled Syringe to Device	
Case Study B: LCM- From Pre-filled Syringe to Device  Case Study C: Autoinjection Devices and the Introduction of  Connectivity as Part of the Life Cycle Management	
Case Study C: Autoinjection Devices and the Introduction of	
Case Study C: Autoinjection Devices and the Introduction of Connectivity as Part of the Life Cycle Management	
Case Study C: Autoinjection Devices and the Introduction of Connectivity as Part of the Life Cycle Management  Summary of Case Studies and Q&A	Michael Betz, <i>Roche</i>
Case Study C: Autoinjection Devices and the Introduction of Connectivity as Part of the Life Cycle Management  Summary of Case Studies and Q&A  Coffee Break  Pre-filled Syringes and OPEs - The REACH Impact on	Michael Betz, <i>Roche</i>
	Focus Topic: Life Cycle Management: From Pre-filled to Syringes / Combination Products  Life Cycle Management: Best Practices and Pitfalls  Coffee Break  Fully Integrated Safety System: A New Option for the Product Life Cycle Management from Vial to PFS  PLAJEX™ and Safe'n'Sound® - Compatibility Established to Serve Pharma Clients for Product Life Cycle Management  Case Study: A Supplier's Perspective  Lunch Break  PDA Interactive: Roundtable Discussions of Different Case Studies  Moderator.  Case Study A: LCM - From Lyo Vial to Pre-filled Syringe

1. February 2017, 4:12 PM

#### Tuesday, 14 March 2017

**9:00 Welcome and Introduction** Georg Roessling, *PDA Europe* 

Roger Asselta,

Genesis Packaging, Conference Co-Chair

Derek Duncan, LIGHTHOUSE, Conference Co-Chair

9:10 Keynote Presentation Hanns-Christian Mahler,
Challenges for Biotech Drug Products at the
Interface of Formulation, Process and Primary Packaging

Opening Plenary

Moderator: Renaud Janssen, Datwyler

9:40 EU Updates & Inspection Findings

Manuel Ibarra, AEMPS

10:10 US Pharmacopeia Updates

Desmond Hunt, USP

10:40 Ongoing Revision on USP Chapters <660> and <1660>

Bettine Boltres, Schott

11:10 What's New in Japanese Pharmacopoeia 17 - A User's Perspective

Jörg Zürcher, Bayer

11:40 Q&A, Discussion

12:00 Lunch Break, Poster Session & Exhibition

#### **PARALLEL TRACKS 1 TRACK A** TRACK B **Components & Materials Processing** Moderator: **Bettine Boltres**, *Schott* Moderator: Michael Spallek, Rommelag ENGINEERING 13:00 Silicone-Free Pre-Filled Glass Jeffrey Brake, Particle Reduction with Stopper Thomas Syringes: From Feasibility to Reality Jochimsen, Gore Processing Atec Pharma Nicolas Eon, Schott 13:30 Premium Technology for Primary Dave Lisman, Aseptic Powder Processing for Elke Glass Container Surface Control Nipro Pharma New Dual Chamber Tubes Sternbergerand Enhancement to Container A First Assessment Ruetzel, Packaging and Drug Stability Harro Hoefliger

X-Cartridge: A New Generation of Alessandro Capping Operation and Kamila Rau- Glass Primary Containers for Mod-Morandotti, ern Drug Delivery Devices (DDD) Ompi Capping Operation and Qualification Concept Hoffmann-L
---

#### 14:30 Coffee Break, Poster Session & Exhibition

	TRACK A		TRACK B						
	Components & Mater	ials	Processing						
	Moderator: Michael Spallek, romme	elag	Moderator: <b>Galen Shi,</b> <i>Eli Lilly</i>						
15:00	Ethylene-Norbornene Copolymers as High Purity Olefinic TPEs for Primary Packaging	Wilfried Hatke, TOPAS Advanced Polymers	Bringing a Valuable Technology a Step Further: Advances in Vial Isolation 2017	Tim Wenzel, Friedrich- Alexander University, Erlangen					
15:30	Impact of the New USP <661> Guidance – a Resin Supplier's View	James Stern, Borealis	How the Adoption of Single Use Systems (SUS) Improves the Safety, Efficiency and Flexibility of Final Filling Processes	Mathieu Labedan, Sartorius Stedim					
16:00	Q&A, Discussion		Q&A, Discussion						

#### 16:30 Coffee Break, Poster Session & Exhibition

		PARALLEL TRAC	CKS 2					
	TRACK A		TRACK B					
	Components & Glas	SS	Process Analysis					
	Moderator: Jörg Zürcher, Bayer		Moderator: <b>Klaus Wuchner,</b> Janssen J&J					
17:00	Risk Mitigation Addressing the Delamination Propensity of Tubular Glass Vials	Volker Rupertus, Schott	Glass Packaging Breakages: Optimization of Container Filling Lines by In-situ Shock-Logger Detection Investigation	Nicola Favaro, Stazione Sperimentale Del Vetro				
17:30	Evaluation of Glass Delamination in Pharmaceutical Vials	Dominique Ditter, Hoffmann- La Roche	Finding the Weak Points in the Filling Line: Force Analysis by In-Line Monitoring	Evan R. Justason, Smart Skin Technologies  Andreas Graser, Hoffmann- La Roche				

	TRACK A		TRACK B	
	Components & Gl	ass	Process Analy	rsis
18:00	Addressing Cracks in Pharmaceutical Containers with new Glass Material	Kyle Hoff, Corning	Reducing Vial Breakage and Protecting Handlers of Highly Potent Drugs	Hironori Yoshida, Nipro Pharma Packaging
18:15	Q&A, Discussion		Q&A, Discussion	
18:30	End of Conference Day 1			
19:00	Networking Event in Barcelona			



#### Wednesday, 15 March 2017 **MORNING SESSION** 7:30 Open Forum: Packaging Science Interest Group (IG) Meeting Derek Duncan, LIGHTHOUSE **PARALLEL TRACKS 3 TRACK A TRACK B Novel Sealing Concepts for Lyophilized Products** Modeling Moderator: Roger Asselta, Genesis Packaging Moderator: Derek Duncan, LIGHTHOUSE 9:00 Challenges for Vial Sealing Michele Arduini, Modeling the Discharge Behavior Christoph A. in the Freeze Dryer IMA of BFS Infusion Bottles by Finite Kaschta, Element Analysis and Experimental Rommelag Verification **ENGINEERING** 9:30 The Appearance of Plastic Caps as Miriam Beyer & Investigation of Stopper Pop-out Raphael Kaelin, a New Sealing Solution Kolja Richlowski, by Means of Finite Element Analysis Datwyler WEST 10:00 Using a Process Control Strategy Yusuf Oni, Critical Consideration in Time-Qingyu Zeng, to Enable an Adequate Container Bristol-Myers Dependent Evaluation and Model-**WEST** Closure System Squibb ing for Rubber Stopper Seal Performance of Vial Container Closure 10:30 Q&A, Discussion Q&A, Discussion **Coffee Break, Poster Session & Exhibition** 11:00

	TRACK A		TRACK B					
	CCI at Cryogenic Cond	itions	Pharmaceutical Companies' Challenges					
	Moderator: <b>Roman Mathaes,</b> <i>LONZ</i>	A	Moderator: <b>Daniel Wagner,</b> Sanofi					
11:30	Modeling of Container Closure for Cryogenic Storage of Parenteral Drug Products	Ronald Iacocca, Eli Lilly	Drug Product Vial Development, Key Challenges to Modernizing an Established Platform	Scott Stiffler, Eli Lilly				
12:00	Cryogenic Parenteral Packaging	Chris Folta, Janssen J&J	PFS Stoppering Challenges: Optimisation of Filling Line Parameters to Avoid Liquid between Plunger Stopper and Syringe Glass Wall	Charlotte Pellet, Sanofi				
12:30	Q&A, Discussion		Q&A, Discussion					
13:00	Lunch Break, Poster Session & Ex	hibition						

	Closing Plenary Container Closure Integrity (CCI)	Moderator:	Roger Asselta, Genesis Packaging
14:00	An Industry Perspective on Application of CCIT for Sterile Biotech Products		Roman Mathaes, <i>LONZA</i>
	Biotech Products		Klaus Wuchner, Janssen J&J
14:30	USP Update on CCIT		Donald Singer, <i>USP</i>
15:00	A Case Study for a Renovated Approach to Seal Quality and Contain Closure Integrity Testing across the Lifecycle of Sterile Products	ner	James Mellman, <i>Novartis</i>
15:30	The Effect of a Plunger Surface Roughening Treatment on CCI: Evaluation of Inherent Package Integrity by Helium Leak Detection in the Vacuum Mode	1	Brandon Zurawlow, Whitehouse Labs
16:00	CCI Test Method Development using Headspace Analysis to Measur Gas Flow into a Defective Container	e	Derek Duncan, <i>LIGHTHOUSE</i>
16:30	Panel Discussion: Container Closure Integrity	1oderators:	Roger Asselta, Genesis Packaging
			Bettine Boltres, Schott
17:00	End of Conference & Farewell		







The Parenteral Drug Association presents:

# 2<sup>nd</sup> PDA Europe Annual Meeting

Global Healthcare of the Present & the Future



13-14 June 2017


Hilton Berlin

**Berlin | Germany** 



#### TO EXHIBIT:

PDA meetings and conferences are a great opportunity for your company to gain on-site exposure in front of highly-qualified, upper-level professionals in the pharmaceutical and biopharmaceutical industry. Exhibition and Sponsorship Opportunities are available. A basic exhibition package for this event is priced **1.895 Euro net (table-top).** For more information please contact **expo-europe@pda.org** 



# **Training & Education Program**

europe.pda.org



PDA Education offers courses that are developed and taught by experts. They are uniquely targeted to professionals involved in the development and manufacturing of quality pharmaceutical and biopharmaceutical products.

#### **Facts that Make a Difference**

- Up-to date training courses and workshops taught by internationally renowned experts
- Wide range of training courses with hands-on experience to drive expertise, awareness, and innovation
- Customized in-house training courses and workshops available



# PDA Education Program

#### 13 March 2017

#### **Elastomers**

One-Day Training Course

#### 13 March 2017

### **Secondary Packaging for Parenterals**

Pre-Conference Workshop

#### 16 March 2017

## **Container Closure Development**

One-Day Training Course

#### 16-17 March 2017

## **Container Closure Integrity Testing**

Two-Day Training Course

#### 16-17 March 2017

#### **Track and Trace**

Two-Day Training Course

#### 16-17 March 2017

**Extractables & Leachables** 

Two-Day Training Course

# Elastomers

#### Overview

Among others the Agenda will cover the following topics:

- Elastomeric Compounds: Composition
- Manufacturing Process for Elastomeric Closures
- Extractables and Leachables
- Particles Reduction during Closure Processing
- Ready-for-Sterilization and Ready-To-Use Closures
- Regulatory Requirements for Elastomeric Closures

All participants are invited to submit their elastomer related questions, issues and practical problems until **24 February 2017** to PDA Europe training department **training-europe@pda.org** 

All these and further questions will be addressed during this interactive workshop.

#### Who Should Attend

Scientific Officers, Operating Officers, Directors, Principal Scientists in

- Packaging
- Drug Product Manufacturing
- · Product Design
- Technical Support
- Drug Product Process Development
- Drug Development, Design & Delivery
- Clinical Trial Material Supply
- Process Development
- Quality Assurance Compliance and Audit

#### **Learning Objectives:**

- Understand the origin of Extractables and Leachables from elastomeric closures
- Learn about the potential impact of component sterilization on closure properties
- Understand past and upcoming regulatory changes for elastomeric closures
- Learn about the effect of closure washing on visible particle reduction
- Inform yourself on possibilities and limitations in closure design
- Learn about the advantages of Ready-for-Sterilization and Ready-To-Use closures

#### **Training Course Leader**



Renaud Janssen, Ph.D., Head of Regulatory Affairs and Chemical Compliance, Datwyler

Renaud Janssen graduated as a chemical engineer from Leuven University, Belgium. In 1988 he joined Helvoet Pharma, now Datwyler Sealing Solutions, in Belgium where he has been holding various positions in R&D, Quality and Technical Support on local and global level. Currently Renaud is Senior Manager Global Scientific Affairs for the Healthcare segments of Datwyler Sealing Solutions. Renaud serves on several standardization and pharmacopoeial committees.

#### **Trainers**

**Bram Jongen,** Head of R&D Container Closures and Injection Systems, Datwyler **Thomas Jochimsen,** Manager, Atec **Reinhold Zimmermann,** Vice President Continous Improvement, West

9:45	What are the consequences of elastomeric compound selection for Extractables & Leachables?	Dunan Ingana
10:30	<ul> <li>Composition of elastomeric closure compounds</li> <li>Clean extractable profiles as key attribute of compound development</li> <li>Translation of application requirements to closure compositions</li> </ul>	Bram Jongen, <i>Datwyler</i>
	Coffee Break	
10:50	<ul> <li>Which closure properties might be influenced by different sterilization methods?</li> <li>Extractables &amp; Leachables, mechanical characteristics, functional performance</li> <li>Steam versus gamma irradiation</li> </ul>	Reinhold Zimmermann, <i>West</i>
11:10	How are elastomeric closures related to ICH Q3D 'Elemental Impurities' and to pharmacopoeia?  Overview of pharmacopoeial requirements Elastomeric closures in relation to 'Elemental Impurities' regulations DMF's for elastomeric closures	Renaud Janssen, <i>Datwyler</i>
12:00	<ul> <li>How can helium leak testing be used for Container Closure Integrity Testing?</li> <li>A comprehensive overview of ongoing regulatory changes in the Container Closure Integrity Testing area</li> <li>The most popular test methodologies explained</li> <li>Method development using helium leak equipment</li> <li>Some limitations using helium leak equipment</li> </ul>	Bram Jongen, <i>Datwyler</i>
12:30	<ul> <li>What are the main aspects to consider for recommending closures?</li> <li>Material, drug compatibility, drug delivery, drug administration etc.</li> </ul>	Reinhold Zimmermann, <i>West</i>
13:00	Lunch Break	
13:45	How can particle reduction be qualified through stopper washing?	Thomas Jochimsen, Atec
14:30	Which are the specific considerations pharmaceutical packaging development has to take into account when designing elastomeric components?  • An A-Z pictorial description of the closure manufacturing process Standard manufacturing   Coated closures   Lined seals	Bram Jongen, <i>Datwyler</i>
15:15	Coffee Break	
15:45	Which impact do stopper elastomer material and closure processing steps have on residual moisture in the closure and in the freeze-dried product over long-term storage?  Steam sterilization  Drying conditions	Reinhold Zimmermann, West
16:15	<ul> <li>What are the advantages of RfS and RTU closures?</li> <li>Cost savings related to RfS and RTU elastomeric closures</li> <li>Validation activities related to RfS and RTU closures</li> <li>Market evaluation of RfS and RTU closures</li> </ul>	Renaud Janssen, <i>Datwyler</i>
17:00	<b>Open Discussion</b> of student questions, issues, and practical problems with elastomers	

# Container Closure Development

#### Overview

The course will give an overview on how to develop a container closure system for parenteral products. Starting with setting up of a product profile of the final product container, all aspects will be covered, like selection of materials, assessment of container closure systems, specification and documentation of components and entire systems. In addition, current hot topics such as glass delamination and container closure integrity testing will be discussed.

For all topics of the agenda presentations will be given. The participants are invited to add own experience, ask questions and offer issues to be discussed within the group and/or with the trainer. The intention is to work in an open workshop-like atmosphere.

#### **Who Should Attend:**

- Scientists in Drug Product Development
- Scientists/ Engineers in Packaging Development
- Regulatory Affairs Experts

#### **Learning Objectives:**

- Set-up of a target product profile of a container closure system
- Select appropriate container closure materials, components, and systems
- Apply the appropriate regulations and standards to container closure systems for parenteral formulations
- Prepare a development plan of a container closure systems from the early development until market phase
- Specify container closure system regarding technical aspects and regulatory requirements
- Understand compendial requirements and quality as well as technical standards regarding container closure components and systems



Jörg Zürcher, Senior Scientist, Bayer

Jörg Zürcher is a pharmacist by education. After his studies and PhD thesis at the Free University in Berlin, he started his career in the pharmaceutical industry 1990 with the former Schering AG. He is responsible for the development of container closure systems and application devices at Bayer HealthCare and has more than 25 years' experience in that field. His current focus is the development of systems/devices for liquid and parenteral as well as ophthalmic dosage forms.

#### Thursday, 16 March 2017 9:00 - 17:00 9:00 **Welcome & Introduction** 9:10 **Setting up a Target Profile** Influence of formulation (small molecule, biological) Use of product (patient, nurse, physician....) Regulatory requirement 9:30 **Material Selection** Ph.Eur. / USP / JP Plastic vs. glass · Coating of material Stopper material 10:30 **Coffee Break** 11:00 **Selection of Packaging Solution Assessment of Packaging Solutions - Development Data** 11:30 • Testing of injection vials/bottles and their respective components • Testing of pre-filled syringes (PFS) and their respective components • Extractables & Leachables (E&L) testing Mechanical and functional testing 12:30 **Lunch Break** 13:30 **Manufacturing of Packaging Solutions** Test runs • Process validation (risk assessment, critical parameters) Container closure integrity (physical vs. microbiological testing – USP 1207) • Shipping test for PFS 14:00 **Setting of Specifications** Technical drawings Technical / quality specification Testing standard, defect evaluation list · Examples **Coffee Break 15:00** 15:30 **Preparing the Submission** Relevant eCTD sections (drug substance and drug product) • Regulatory drawings • DMF for US 16:00 **Routine and Release Testing** Certificates · Routine E&L testing Reduced testing 16:15 **Change Management** • EU requirements 16:30 Wrap-up, Discussion, Q & A 17:00 **End of Training Course**

# Container Closure Integrity Testing

#### Overview

This workshop focuses on theoretical and practical fundamentals of various CCI testing technologies and provides a systematic approach to applying these testing methods for CCI verification throughout drug product lifecycle. The Workshop will enable the participants to implement CCI testing strategies to ensure adequate drug product protection and be compliant with relevant regulatory and compendia requirements. In this Workshop, participants gain critical problem solving skills through:

- interactive discussions with a panel of cross-functional technical experts consisting of CCI testing laboratory experts, testing instrument suppliers/manufacturers, and pharmaceutical packaging development engineers
- hands-on testing training on the newest innovations and state-of-the-art instruments
- real-world case studies.

#### **Who Should Attend**

- Parenteral drug packaging engineers and formulation scientists
- · Laboratory scientific staff and managers
- Parenteral manufacturing staff
- Sterility Quality Assurance
- Regulatory affair scientists
- Pharmaceutical packaging component manufacturing staff

Presentation of Technology, Instruments Demo and Hands-on Training kindly supported by:

ATC, Genesis Packaging Technology, Lighthouse, pti, Sartorius, Wilco

#### **Learning Objectives**

This workshop utilizes lectures, case studies, and interactive hands-on training on testing instruments to provide insight into the latest developments of Container Closure Integrity (CCI) Testing, with focus on achieving the following key objectives:

- Understanding up-to-date regulatory and pharmacopeia requirements on CCI.
- Defining CCI requirements for various container and drug product types using a risk-based approach.
- Explaining working principles of various CCI testing techniques and their practical applications, with focus on

deterministic methods such as tracer gas detection (e.g. helium leak detection), electrical conductivity and capacitance (HVLD), vacuum decay leak detection, laserbased gas headspace analysis, mass extraction leak test.

- Selecting and applying appropriate testing methods for both laboratory and in-process testing to formulate comprehensive package integrity verification profiles.
- Defining CCI testing method development and validation approach and best practices.
- Avoiding common issues and pitfalls in CCI testing applications



Lei Li, Ph.D, Associate Engineer Advisor Delivery and Device R&D, Eli Lilly

Lei Li currently serves as an engineer advisor at Delivery and Device R&D, Eli Lilly and Company. Lei has 9 years of experience in pharmaceutical and medical device industry, with focus on developing API and drug product packaging in support of clinical development and product commercialization, and establishing cold-chain distribution for biologic products. His current responsibilities include developing package integrity verification profiles for Lilly's diverse pipeline portfolio, developing and validating CCI testing methods, and supporting

commercial control strategy development for CCI verification throughout drug product and device life cycle. He is a frequent speaker at PDA conferences and author of peer-reviewed articles and book chapters on CCI test methods. Lei Li received his Ph. D. in Analytical Chemistry from West Virginia University; prior to joining Eli Lilly, he worked at GE Plastics as an analytical and material scientist.

#### Thursday, 16 Mar 2017

9:00 - 18:00

#### 9:00 Day-1 Review

Friday, 17 Mar 2017

9:00 - 16:30

#### 9:00 Welcome

#### 9:30 **CCI Introduction, Regulatory Requirements, and Industry Trends**

- Introduction to container closure integrity
- Regulatory requirements

#### 10:30 **Coffee Break**

#### 11:00 **CCI Introduction, Regulatory Requirements,** and Industry Trends (Continued)

- · Compendia updates: USP 1207 revision updates, EP
- PDA TR 27 revision updates

#### **Introduction to CCI Test Methodologies** 11:30

- Classification: deterministic vs probabilistic; microbiological vs physicochemical methods; by limit of detection
- Key method performance characteristics
- Laboratory bench-top testing v.s. online 100% inspection
- · CCI v.s. Seal Integrity Testing

#### 12:00 **Lunch Break**

#### 16:00 **Advanced CCI Testing Technologies** and Seal Quality Testing Technologies

- 1. HVLD
- 2. Vacuum and pressure decay
- 3. Mass Extraction

#### **Coffee Break** 15:30

#### 16:00 **Advanced CCI Testing Technologies** and Seal Quality Testing Technologies

4. Tracer gas (helium leak detection)

Day-1 Summary; Case Study Assignment

- 6. Seal Integrity methods

## **Development of CCI Testing Strategy**

9:30

- Testing requirement definition
- Testing strategy development
- Examples and case study exercise

#### 10:00 Approaches to **CCI Testing Method Selection**

- Method selection considerations
- Testing method selection guidance
- Examples and case study exercise

#### **Coffee Break** 10:30

#### 11:00 **Instrument Demo and Hands-on Training:**

- 1. HVLD station
- 2. Vacuum decay
- 3. Mass Extraction

#### 12:30 **Lunch Break**

#### 13:30 **Instrument Demo and Hands-on Training:**

- 4. Headspace
- 5. Helium leak detection
- 6. Seal quality tests

#### 14:30 **Coffee Break**

#### 15:00 **Development and Validation of Integrity Test Methods**

- Method development best practices
- Method validation strategy
- Pitfalls and solutions

#### 16:00 **Course Summary**

#### 16:30 **End of Workshop**

- 5. Headspace analysis

#### 18:00 **End of Day 1**



17:30

Jennifer Roark, B.S., Manager Chemistry & Container Testing, Eurofins Medical Device Testing

As Manager of Chemistry and Container Testing, Jennifer Roark oversees testing to support the container and package testing needs of both pharmaceutical and medical device clients. Her group specializes in various CCI testing technologies such as vacuum decay, high-voltage leak detection, FMS oxygen headspace, pressure decay, and dye immersion. She also supervises the physiochemical testing associated with the USP, EP, and JP General Chapters on plastics, elastomeric closures, glass, and container performance testing. Jennifer has more

than 22 years of analytical testing experience and serves as one of Eurofins' leading subject matter experts for Extractables and Leachables Testing. She currently serves on ASTM Committee E55 on the Manufacture of Pharmaceutical and Biopharmaceutical Products, Subcommittee E55.04 General Biopharmaceutical Standards, leading the efforts to draft standard WK43945. Jennifer Roark has been involved with small molecule methods development and validation for over 12 years, and has co-published a series of articles on method validation.

# Track and Trace

# How to implement Pharma Serialization, Tamper Evidence and the FU-Falsified Medicines Directive

#### **Overview**

The training course will support you in collecting, sorting and proper understanding of the relevant contained information related to the defined two EU-safety features, which are a unique identifier, and tamper evident closures to be applied to the packaging of medicinal products within the EU 9th February 2019 the latest. Also this course will deal with the existing and emerging global serialization and track and trace requirements for medicines and their packaging in markets such as China, Korea, US and others.

#### **Who Should Attend**

This course is designed for executive and operational managers of pharmaceutical companies, especially from packaging operations, as well as IT and engineering staff, responsible for the implementation or operation of the new system. Suppliers of packaging and authentication technology and pharmaceutical packaging companies are also welcome.

#### **Learning Objectives**

It is the course's goal to inform about the latest developments in serialization & authentication coming from the EU directive 2011/62/EC and the corresponding Delegated Regulation as published in the Official Journal of the European Union. Generally the challenges and solutions how to comply with serialization, tamper verification and packaging requirements of medicinal products in the different markets are core content of this course. Best practice examples will demonstrate how the new European requirements on verification of the authenticity of each single medicinal product can be put into practice.



Dieter Mößner, Project Engineer Pharma, Edelmann GmbH

For 19 years, Dieter has been working as a team leader in the pre-press area at Edelmann GmbH, responsible for artwork services and for print data communication. Dieter composed parts of the guidelines "Braille on Folding Cartons", published by the European Carton Makers Association ECMA. He is Convenor of CEN/TC 261/SC 5/WG 12 "Marking". This working group at the European Committee for Standardisation CEN has created the European standards EN 15823:2010 "Braille on Packaging for Medicinal Products" and EN 16679:2014 "Tamper

Verification Features for Medicinal Product Packaging". Since March 2013, he has been chairman of the packaging standards committee NAVp at the German Standards Institute DIN.



**Thomas Brueckner,** Head of Pharmaceutical Affairs, Medical Devices, Counterfeit Protection, Pharmacopoeial Matters and Standardization, BPI e.V.

Since 2003 Thomas Brueckner holds the position as Head of Pharmaceutical Affairs, Medical Devices, Counterfeit Protection, Pharmacopoeial Matters and Standardization at BPI e.V. He is member of various DIN, CEN and ISO committees, the Board of Trustees of the Foundation for the Promotion of Standardization in the field of medicine, of the German Pharmacopoeia Commission and the Homeopathic Pharmacopoeia Commission and

of the Executive Board of "securPharm e.V." From 1992 - 2003 he worked as Control Manager, Information Officer and DRA Manager at different pharmaceutical companies. Thomas Brueckner holds a diploma in Pharmacy from Martin Luther University of Halle-Wittenberg and a degree as Healthcare economist (ebs) from the European Business School in Oestrich-Winkel.



Klaus Egner, Engineering and Maintenance, Merck

Klaus Egner started his career in the area of automation at Merck in 1998. At first, he was responsible for laboratory and pilot plant units. From 2005 on he worked in the automation area, e.g. MES, production and packaging of solid dose. Since 2011 his focus topic is Track & Trace in Packaging. Klaus Egner obtained his degree in Engineering from Technical University Darmstadt. Additionally, he passed a continuing education as Master of Technical Management (CCI).

	day, 16 March 2017	9:00 - 18:3
9:00	Welcome - Overview and Target of the Training Course	
9:15	Overview Global Serialization Requirements	Thomas Brueckner
10:10	Coffee Break	
10:30	Requirements EU-Falsified Medicines Directive 2019/securPharm	Thomas Brueckner
11:15	Implementation of Serialization - Technical Challenges	Klaus Egner
12:00	Lunch Break	
13:00	Print Quality of Barcodes and 2D Matrixcodes	Dieter Moessner
13:45	How to Comply to Serialization – Regulatory Tasks	Thomas Brueckner, Klaus Egner
14:45	Coffee Break	
15:00	Site Visit at a Packaging Manufacturer Facility	Site Visit Requested
18:30	End of Day 1	
Frida	y, 17 March 2017	8:30 - 16:0
08:30	DIN EN 16679 "Tamper Verification Features for Medicinal Product Packaging" – Practical Implementation	Dieter Moessner
09:15	Barcodes in the Pharmaceutical Manufacturing Process	Dieter Moessner
10:00	Coffee Break	
10:30	Technical and Organizational Implementation of Serialization at the Pharmaceutical Manufacturer	Klaus Egner
11:30	Coding / Serialization / Artwork at the Manufacturer of Printed Packaging Materials	Dieter Moessner
13:00	Lunch Break	
14:00	Coding Rules for Medicines Requiring Verification / securPharm	Thomas Brueckner Klaus Egner
15:00	Qualification and Validation of Serialization and Tamper Verification Technologies in Pharma Packaging	Dieter Moessner
15:30	Coffee Break	
15:30	Current Developments, Q & A, Discussion	Dieter Moessner
16:00	End of Course	

# Extractables & Leachables

Including: Important Regulatory Updates – Case Study Section: Selection of Toxikon's most interesting Case Studies, presented over the last 10 years!

#### Overview

When making Parenteral Drug Products, pharmaceutical companies are faced with the need to further investigate the materials that will be in contact with the drug product, either during manufacturing, intermediate storage, storage in its final packaging, or during the delivery of the drug to the patient. While historically, the potential safety issues were the main driver in these kinds of investigations, recently, also quality issues – i.e. for biopharmaceuticals – have become an additional concern. This workshop will look at "Extractables & Leachables" from many different angles: Definitions, Regulatory, Material & Polymer Science, Analytical E/L Methodologies, Safety Assessments, Study Design for different parenteral primary packaging systems, as well as for injection devices.

#### **Learning Objectives**

Upon completion of this workshop, you will be able to:

- Explain in detail the current regulatory requirements for container/closure qualification form an E/L perspective.
- Explain the upcoming changes in regulations, standards and recommendations from PQRI, USP and BPOG and how these changes could impact a future evaluation of a pharmaceutical C/C-system.
- Understand the materials of construction and their composition – of container closure systems, and how they could impact the safety and quality of a parenteral drug product.
- Put together an evaluation program (review of provided documentation, analytical testing) of different types of parenteral drug product container/closure systems.
- Perform a safety/risk assessment of analytical results, obtained after completion of an E/L study.

#### **Who Should Attend**

- Pharmaceutical Packaging and Device Engineers
- Production Engineers, using SU systems
- Regulatory Affairs Officers
- Pharmaceutical R & D Managers
- Analytical Chemists, working on E/L
- Quality Assurance Officers



**Dennis Jenke,** PhD, Chief Executive Scientist, Triad Scientific Solutions

Dennis Jenke is the Chief Executive Scientist for Triad Scientific Solutions, a provider of science-based solutions to plastic/product compatibility challenges associated with packaging, manufacturing equipment and delivery devices in the pharmaceutical, cosmetic, food and related industries. He was a Distinguished Scientist at Baxter Healthcare Corporation where for more than three decades he lead a team whose primary responsibility includes the assessment of material/product compatibility, specifically with respect to establishing the suitability for

use of packaging systems, manufacturing systems and administration devices for pharmaceutical products (for example, extractables/leachables and product ingredient binding). He has published extensively in the areas of analytical chemistry, environmental science and material/solution compatibility and serves as an expert reviewer for numerous pharmaceutical and analytical journals. He is the author of the book Compatibility of Pharmaceutical Solutions and Contact Materials; Safety Considerations Associated with Extractables and Leachables and a contributing author to the Leachables and Extractables Handbook. Dennis Jenke is a member of numerous industry groups whose charter is to establish best demonstrated practices in the area of material/solution compatibility.

#### Thursday, 16 March 2017

9:00 - 18:00

#### Introduction on Extractables & Leachables (E/L)

- ▶ What is the importance of a good E/L-qualification?
- ► Historical cases of leachables, impacting the quality or the safety of a drug product
- ► Regulatory requirements (FDA, EMA...) for primary packaging

#### Understanding the Materials, Used in the Manufacture of Pharmaceutical Containers & Closures

- ► Types of polymers examples in medical/pharmaceutical use
- ► Understanding the composition of polymers
- ► The issues with glass in parenteral applications

#### Analytical Techniques to Perform Extractables & Leachables Research

- ► The importance of sample preparation: the corner stone in E/L research
- ▶ What are the target compounds for material research
- ▶ How does a classification of these compounds assist in finding the right analytical technique
- ► From basic "screening" methodologies to state-of-the-art equipment

#### How to Set-up Extractables & Leachables Studies

- ► Selecting the right conditions for extraction
- ► How to select the right compounds to monitor in a leachable study
- ► Designing a leachable study

#### FULL Session on Updates of E/L- Regulations, Standards and Recommendations

- ► Pharma Packaging:
  - Preview of the final PQRI Parenteral Drug Product (DPD) & ODP Chemistry group
  - Update on the most recent developments on the USP <661> chapters
- ▶ Devices
  - Chemical characterization of devices according to ISO 10993-18: What changes are coming up?
  - Upcoming Revisions of the USP <87> and USP <88>: Where could it go to?
- ► (Bio)Pharmaceutical Manufacturing
  - The BPOG protocol
  - Where is USP with the update on the USP <661.3> Plastic Manufacturing Components standard

#### How to Perform a Safety Evaluation - Risk Assessment on Extractables & Leachables

- ► Toxicology 101
- ► EMA Guideline on Genotoxic Impurities
- ► ICH M7 (DNA reactive Impurities) and its suggested staged approach
- ► The Threshold Concept of PQRI (OINDP and PDP/ODP)
- ► Examples



#### Piet Christiaens, PhD, Scientific Director, Toxikon Europe

Piet Christiaens received his Ph.D. from the Analytical Chemistry Department of the University of Leuven (Belgium) in 1991. From 1992 to 1997, he was Lab Manager in two Analytical Contract Laboratories. From 1997 to 2000, he worked as an independent consultant with Shell Chemical Company in Houston, Texas where he conducted research on a new hydrogenation catalyst system for Hydrogenated Triblock Co-Polymers (Kraton Polymers). Since 2001, Mr. Christiaens has been Scientific Director at Toxikon Europe where he develops analytical

methods and protocols for both extractables and leachables studies for the Medical and Pharmaceutical Industries. Mr. Christiaens oversees all laboratory operations at Toxikon Europe and is also supports the European business development team.

#### Friday, 17 March 2017

9:00 - 16:30

#### E/L Testing for a Pre-filled Syringe (Glass & Polymer)

- ▶ Glass Syringes: the issues with tungsten, glue residues and silicone oil and glass metals leaching
- ▶ The Issue with rubbers: the plunger, the needle shield or the tip cap: different approaches needed?
- ► The impact of secondary packaging option or necessity?
- ► Setting up extractable & leachable studies for a pre-filled Syringe

#### **E/L Testing for Lyophilized Drug Products**

- ▶ Primary packaging for the lyophilized drug product modus of interaction with the DP
- ▶ Impact of the "21CFR Part 4" on combination products, used in the administration of a lyo DP
- ► Critical aspects when designing leachable studies for lyophilized DP
- ▶ Integration of the administration procedure (e.g. IV-set, pump system) in leachables evaluation

#### How to Look at Injection Devices from an E/L Perspective

- ▶ Medical device regulations versus pharma packaging
- ► Test selection process for devices: What to do?
- ▶ USP and ISO 10993 series for biocompatibility testing
- ► Case: Injection device

#### **Large Volume Parenterals**

- ► The challenge in E/L testing for LVP's
- ► Primary packaging for LVP's critical materials and components
- ► Secondary packaging for LVP: critical points to consider

#### E/L Testing for Disposable and Single-Use Systems in Bioproduction

- ▶ How to classify the risk of different single-use systems in the bioproduction process?
- ▶ Understanding BPSA & BPOG recommendations, and how they can be implemented in the study design
- ▶ Performing E/L studies on filters: potential approaches



**John lannone,** Director of Extractables/Leachables and Impurities, Albany Molecular Research, Inc. (AMRI)

John Iannone has a background in Biomedical Engineering from Boston University, where he later became a research engineer. Since going from Academia to Industry 13 years ago, John has assisted multiple pharmaceutical & medical device companies with the development of their product safety evaluation strategies. Previously a Technical Specialist at Toxikon, he now is the Director of Extractables/Leachables and Impurities at Albany Molecular Research, Inc (AMRI). His areas of expertise include Material Qualification

& Biocompatibility, Extractables & Leachables, Chemical Characterization, and attainment of Biological or Toxicological risk assessments for medical devices, pharmaceutical container systems, bioprocessing systems, and combination products. John has given numerous technical presentations and has led several workshops on Extractable & Leachable Considerations, Biocompatibility, Microbiology, and Regulatory Testing Requirements. He also participates in the development of both industry groups' recommendations and regulatory guidelines through Expert Panel membership, global Technical Committees, and industry collaborations. Additional responsibilities have included providing technical consultation to clients regarding unique testing requirements in an effort for them to meet global regulatory expectations.

7 Oct 2017 and SAVE!

# **2017 PDA Europe Conference, Exhibition**

# The Universe of Pre-filled Syringes & Injection Devices



**7-8 November 2017** 

Austria Center Vienna | Austria



#### VENUE

#### **Hotel Porta Fira**

Plaza Europa, 45 08908 – Hospitalet de Llobregat Barcelona, Spain Tel: +34 93 297 35 00 http://hotelbarcelonaportafira.com/en/

#### **Special Rates**

# Single Room 108.90€ per room and night Double Room 133.10€ per room and night

Housing at the selected hotel will be in high demand, so we strongly recommend making your reservations early.

#### **GENERAL ADDRESS**

PDA Europe gGmbH Am Borsigturm 60 13507 Berlin, Germany Tel: +49 30 4365508-0 Fax: +49 30 4365508-66

#### **SPECIAL REQUIREMENTS**

If you require special accommodations to fully participate, please attach a written description of your needs with your registration form. Specific questions can be directed to registration-europe@pda.org

#### **DIRECTIONS**

 $@ \ Google \ For \ directions \ click \ on \ the \ picture, \ scan \ the \ QR-code \ or \ go \ to \ https://goo.gl/maps/4PvDTH5WEG72$ 

#### **CONTACT INFORMATION**

#### **Registration Customer Care**

Tel: +49 30 436 55 08-10 registration-europe@pda.org

#### **Conference Inquiries**

#### **Melanie Decker**

Director Events & Exhibitions decker@pda.org

#### **Conference Program Inquiries**

#### **Sylvia Becker**

programs-europe@pda.org

#### **Education Program Inquiries**

**Elke von Laufenberg** 

training-europe@pda.org

#### **Exhibition/Sponsorship Inquiries**

Nadjeschda Gomez-Stahl

expo-europe@pda.org



# Registration Form Page 1

#### 14-15 March 2017 | Barcelona | Spain

This PDF-file provides an automatic fill-in function. Your signature, however, is needed in writing.

Your registration is only complete upon filling in and submitting both pages of this form.

Registration	EARLY BIRD DISCOUNT Book by 8 January to	receive € 150* off the conference	e fee o	nly
		All fees given in Euro, exclud	ling V	AT (21 %)
13 March	Interest Group Meeting	IG Meeting Fee		
IG Meeting Pre-filled Syringes		All Participants		400
13 March	Pre-Conference Workshop	Workshop Fee		
Secondary Packaging for Parer	nterals	All Participants		450
13 March	One-Day Training Course	Training Course Fee		
Elastomers	one say manning counce	All Participants		845
14-15 March	Conference only	Conference Fee		
Parenteral Packaging	comercines only	PDA Member		1495
raienterat rackaging		**Nonmember		1795
	* Early Bird 670	€ **Regulatory/Academic		750
Poster Presenter please mark	here (written approval required, conference fee appl	3		
16 March	One-Day Training Course	Training Course Fee		
Container Closure Development	·	All Participants		845
16-17 March	Two-Day Training Course	Training Course Fee		
Container Closure Integrity: Re	gulations, Test Methods, Application	All Participants		1495
16-17 March	Two-Day Training Course	Training Course Fee		
Track and Trace: How to implement and the EU-Falsified Medicines	nent Pharma Serialization, Tamper Evidence Directive?	e All Participants		1495
16-17 March	Two-Day Training Course	Training Course Fee		
Extractables & Leachables		All Participants		1495
	tation as well as mid-session refreshments a s will be given. The fee does not include the ho s at a special group rate.			
**Registration fee includes a one-ye receive the benefits of membership, plea	ar PDA membership if no further special discount is ase check here (same rate applies). □	granted. If you do not wish to	join F	'DA and
Group Registration Discount Regist	er 5 colleagues for the conference at the same time formation on group discounts please contact Ant			
□ Discount for Evhibiti	ng Companies			

Please mark here if your company is an exhibitor to this event and you will receive the conference ticket at the **special price of 995 Euro** 

**per ticket.** No further discounts are applicable with this option (as PDA Membership Discount or Group Ticket discount).

## **Parenteral Packaging**



This PDF-file provides an automatic fill-in function. Your signature, however, is needed in writing.

#### 14-15 March 2017 | Barcelona | Spain

3 WAYS TO REGISTER ONLINE: pda.org/eu-parpack-2017 FAX: +49 30 4365508-66

El EMAIL: registration-europe@pda.org

1 Your Contact Information	If this fo	rm is a	n upda	ite to a	previously sub	omitted fo	orm, pl	lease che	ck here.							
<u> </u>		Mr.		Ms.	Dr.			Nor	ımember			I want to Please s				
								-		10.11						
Name (Last, First, MI) *								PDF	Member	ID Nun	nber					
Job Title *																
Company*							Departme	ent								
Mailing Address																
City									Postal Co	de						
Country				Email												
Business Phone				Fax												
Substituting for																
3 Payment Options	<ul><li>All co mittir</li><li>Poten</li></ul>	sts inc ng doc ntial pa	urring uments irticipa	in conr s by cou	st be clients o	isa affairs	shall b	be borne	by registra	ants. (Th	is app	lies in pa	articul			
By Bank Transfer	By Credit Ca	ard							☐ Pu	ırchas	e Or	der				
Beneficiary: PDA Europe gGmbH	American Exp	oress		Mast	erCard		VISA		Purcha	ase Orc	ler Nu	ımber				
IBAN: DE73 1007 0024 0922 8735 00	•															
BIC (SWIFT-Code): DEUTDEDBBER Bank Address:	For your credit Please send you															
Deutsche Bank, Welfenallee 3-7, D-13465 Berlin, Germany	Billing Address:	:			s contact ir llease send					tration	n-euro	ppe@p	da.or	g		
Your Company VAT I.D.:  This number starts by your course (example: PDA Europe's country count	•		number	r)			PDA	Europe	e VAT I.D	).: DE:	2544	59362				
Your registration is only complete uposubmitting both pages of this form.	on filling in and															
Date					Mandaton	y Signature									_	
300					andator)	, orginature										

CONFIRMATION: Transmitting your filled-in registration form constitutes a binding application for the specific event. PDA Europe will send you a confirmation including payment details. A legally binding contract is concluded once PDA Europe has sent a written invoice by mail to you. You must have a written confirmation (including invoice) to be considered enrolled in a PDA event. Please allow one week for receipt of confirmation letter. Payment must be received or guaranteed by Purchase Order or credit card details on 1st day of event, at the very latest. SUBSTITUTIONS: If you are unable to attend, substitutions are welcome and can be made at any time, including on site at the prevailing rate. If you are registering as a substitute attendee, please indicate this on the registration form. Changes are free of charge until 2 weeks prior to the start of the event. After this two-weeks period, there will be a charge of € 100 per name change. REFUNDS: Refund requests must be sent to PDA Europe. If your written request is received on or before 14 February 2017, you will receive a full refund minus a 150 € excl. VAT handling fee. After that time, no refund or credit requests will be approved. If you are an unpaid registrant and do not attend the event, you are responsible for paying the registration fee. On-site registrants are not guaranteed to receive conference materials until all advanced registered attendees receive them. PDA Europe works PCI-Compliant. EVENT CANCELLATION: PDA reserves the right to modify the material or speakers/instructors without notice, or to cancel an event. If an event must be canceled, registrants will be notified by PDA as soon as possible and will receive a full refund. PDA will not be responsible for airfare penalties or other costs incurred due to cancellation. For more details, contact PDA at info-europe@pda.org or fax to +49 30 4365508-66. DOCUMENTATION: With your signature you give complete picture usage right to PDA and allow to film your exhibition space and intervention in the eve

# 2017 PDA EUROPE CONFERENCES

14 – 15 February	Pharmaceutical Microbiology	*	Porto, Portugal
14 – 15 March	Parenteral Packaging	*	Barcelona, Spain
26 - 27 April	Current Trends in Aseptic Fill & Finish of Prefilled Syringes	*	Lindau, Germany
30 May – 1 June	Virus & TSE Safety Forum	*	Dubrovnik, Croatia
13 - 14 June	2 <sup>nd</sup> PDA Europe Annual Meeting	*	Berlin, Germany
27 – 28 June	Advanced Therapy Medicinal Products	*	Valencia, Spain
19 – 20 September	Pharmaceutical Freeze Drying Technology	*	Cologne, Germany
26 - 27 September	10 <sup>th</sup> Workshop on Monoclonal Antibodies	*	Berlin, Germany
10 - 11 October	Pharmaceutical Cold & Supply Chain Logistics	*	Prague, Czech Republic
7 - 8 November	The Universe of Pre-filled Syringes and Injection Devices	*	Vienna, Austria
21 - 22 November	Outsourcing & Contract Manufacturing	*	Munich, Germany
Subject to change	For latest info: pda.org/pda-europe		Shortlist 1. February 2017, 4:12 PM

\* Events with additional Education Program. More information - pda.org/pda-europe



Conference Information
Melanie Decker
Director Events & Exhibitions
Tel: + 49 30 4365508-19
decker@pda.org

